Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).

被引：0
|
作者：
Cavaliere, Carla
Caffo, Orazio
Ortega, Cinzia
D'aniello, Carmine
Di Napoli, Marilena
Cecere, Sabrina Chiara
Della Pepa, Chiara
Crispo, Anna
Maines, Francesca
Ruatta, Fiorella
Iovane, Gelsomina
Montella, Maurizio
Pignata, Sandro
Facchini, Gaetano
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16569
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16569
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)
    Caffo, O.
    Maines, F.
    De Giorgi, U.
    Fratino, L.
    Lo Re, G.
    Zagonel, V.
    D'Angelo, A.
    Donini, M.
    Verderame, F.
    Ratta, R.
    Procopio, G.
    Campadelli, E.
    Massari, F.
    Gasparro, D.
    Ermacora, P.
    Messina, C.
    Giordano, M.
    Alesini, D.
    Conteduca, V.
    Veccia, A.
    Galligioni, E.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
  • [2] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [6] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.
    Celiz, Pamela
    Pinto, Alvaro
    Puente, Javier
    Manneh, Ray
    Gonzalez Larriba, Jose Luis
    Grande, Enrique
    Alonso, Teresa
    Manuel Sepulveda, Juan
    Rodriguez, Alfredo
    Castellano, Daniel E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
  • [10] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    [J]. CANCER RESEARCH, 2014, 74 (19)
12345